Members of the scientific community have blasted Stanford University and US biotechnology company Auxogyn for their involvement in patenting a test designed to increase the success of in vitro fertilisation (IVF).
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at email@example.com
Eeva, IVF, Auxogyn, Stanford University, Reprogenetics